A Novel Class of Long Non-coding RNAs May Help Explain Increased Susceptibility of Females to Depression
Researchers at Mount Sinai have found that a novel class of genes known as long non-coding RNAs (lncRNAs) expressed in the brain may play a pivotal role in regulating mood and driving sex-specific susceptibility versus resilience to depression. In a study published online, in the journal Neuron on April 17, the team highlighted a specific gene, LINC00473, that is downregulated in the cerebral cortex of women only, shedding light on why depression affects females at twice the rate of men.
“Our study provides evidence of an important new family of molecular targets that could help scientists better understand the complex mechanisms leading to depression, particularly in women,” says Orna Issler, PhD, a postdoctoral researcher in the Nash Family Department of Neuroscience and The Friedman Brain institute, Icahn School of Medicine at Mount Sinai, and lead author of the study. “These findings into the biological basis of depression could promote the development of more effective pharmacotherapies to address a disease that’s the leading cause of disability worldwide.”
Past research has shown that about 35 percent of the risk for depression in both sexes can be traced to genetic factors, and the remainder to environmental factors, primarily stress exposure. Long non-coding RNAs fall into a third category: epigenetic factors, which are biological processes that lead to changes in gene expression not caused by changes in the genes themselves. While research focusing on the role of lncRNAs in mood and depression is in its infancy, Mount Sinai has pushed the boundaries of the science by showing the robust regulation of this class of molecules linked to depression in a brain-region and sex-specific manner.
“Our work suggests that the complex primate brain especially uses lncRNAs to facilitate regulation of higher brain function, including mood,” explains Dr. Issler, “and that malfunction of these processes can contribute to pathologies like depression and anxiety in a sex-specific manner.” Researchers found, for example, that the LINC00473 gene is a female-specific driver of stress resilience that is impaired in female depression. They also learned it is a key regulator of mood in females, in whom it acts on the prefrontal cortex of the brain by regulating gene expression, neurophysiology, and behavior.
To evaluate the contribution of lncRNAs to depression, the Mount Sinai team screened thousands of candidate molecules, and using advanced bioinformatics narrowed the field to LINC00473. Through viral-mediated gene transfer, researchers expressed LINC00473 in adult mouse neurons, and showed that it induced stress resilience solely in female mice. They found that this sex-specific phenotype was accompanied by changes in synaptic function and gene expression selectively in female mice. That discovery, along with studies of human neuron-like cells in culture, led to selection of LINC00473 as the lead candidate. Other genes considered strong candidates are also being actively investigated.
“Our study opens the window to a whole new class of molecular targets that could help explain the mechanisms governing depression susceptibility and resilience, particularly in females,” says corresponding author Eric J. Nestler, MD, PhD, Nash Family Professor of Neuroscience at Icahn School of Medicine, Director of The Friedman Brain Institute, and Dean for Academic and Scientific Affairs. “Long non-coding RNAs could guide us toward better, more effective ways to treat depression and, just as importantly, to diagnose this debilitating condition. Much work remains, but we’ve provided a very promising roadmap to follow moving forward.”
Researchers from the University of Pittsburgh, University of Texas Southwestern Medical Center, and Massachusetts General Hospital contributed to this research.
The study was supported by grants from National Institute of Mental Health (NIMH), Hope for Depression Research Foundation (HDRF) and Brain & Behavior Research Foundation (NARSAD).
About the Mount Sinai Health System
Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.
As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.
Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek and No. 5 on the magazine’s World’s Best Hospitals list. The Icahn School of Medicine at Mount Sinai ranks No. 11 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.
